Nitric oxide in inflammatory bowel disease: a universal messenger in an unsolved puzzle G Kolios, V Valatas, SG Ward Immunology 113 (4), 427-437, 2004 | 577 | 2004 |
Acute respiratory distress syndrome subphenotypes and differential response to simvastatin: secondary analysis of a randomised controlled trial CS Calfee, KL Delucchi, P Sinha, MA Matthay, J Hackett, M Shankar-Hari, ... The Lancet Respiratory Medicine 6 (9), 691-698, 2018 | 573 | 2018 |
Chemokines and T lymphocytes: more than an attraction SG Ward, K Bacon, J Westwick Immunity 9 (1), 1-11, 1998 | 565 | 1998 |
Differential expression of cannabinoid receptors in the human colon: cannabinoids promote epithelial wound healing K Wright, N Rooney, M Feeney, J Tate, D Robertson, M Welham, S Ward Gastroenterology 129 (2), 437-453, 2005 | 411 | 2005 |
The CXC chemokine stromal cell-derived factor activates a Gi-coupled phosphoinositide 3-kinase in T lymphocytes Y Sotsios, GC Whittaker, J Westwick, SG Ward The journal of Immunology 163 (11), 5954-5963, 1999 | 328 | 1999 |
Chemokines: understanding their role in T-lymphocyte biology SG WARD, J WESTWICK Biochemical Journal 333 (3), 457-470, 1998 | 295 | 1998 |
Isoform-specific phosphoinositide 3-kinase inhibitors as therapeutic agents SG Ward, P Finan Current opinion in pharmacology 3 (4), 426-434, 2003 | 266 | 2003 |
The CC chemokine monocyte chemotactic peptide-1 activates both the class I p85/p110 phosphatidylinositol 3-kinase and the class II PI3K-C2α SJ Turner, J Domin, MD Waterfield, SG Ward, J Westwick Journal of Biological Chemistry 273 (40), 25987-25995, 1998 | 236 | 1998 |
Chemokine signalling: pivoting around multiple phosphoinositide 3‐kinases AP Curnock, MK Logan, SG Ward Immunology 105 (2), 125-136, 2002 | 221 | 2002 |
CD28: a signalling perspective SG Ward Biochemical journal 318 (2), 361-377, 1996 | 221 | 1996 |
PI 3-kinase: a pivotal pathway in T-cell activation? SG Ward, CH June, D Olive Immunology today 17 (4), 187-197, 1996 | 221 | 1996 |
Phosphoinositide 3-kinase: a key biochemical signal for cell migration in response to chemokines. Y Sotsios, SG Ward Immunological reviews 177, 217-235, 2000 | 207 | 2000 |
RANTES-activated human T lymphocytes. A role for phosphoinositide 3-kinase. L Turner, SG Ward, J Westwick Journal of immunology (Baltimore, Md.: 1950) 155 (5), 2437-2444, 1995 | 207 | 1995 |
Therapeutic potential of phosphoinositide 3-kinase inhibitors S Ward, Y Sotsios, J Dowden, I Bruce, P Finan Chemistry & biology 10 (3), 207-213, 2003 | 197 | 2003 |
PI 3-K and T-cell activation: limitations of T-leukemic cell lines as signaling models E Astoul, DA Cantrell, C Edmunds, SG Ward Trends in immunology 22 (9), 490-496, 2001 | 180 | 2001 |
Ligation of the T cell co‐stimulatory receptor CD28 activates the serine‐threonine protein kinase protein kinase B RV Parry, K Reif, G Smith, DM Sansom, BA Hemmings, SG Ward European journal of immunology 27 (10), 2495-2501, 1997 | 162 | 1997 |
Evidence that SHIP-1 contributes to phosphatidylinositol 3, 4, 5-trisphosphate metabolism in T lymphocytes and can regulate novel phosphoinositide 3-kinase effectors RW Freeburn, KL Wright, SJ Burgess, E Astoul, DA Cantrell, SG Ward The Journal of Immunology 169 (10), 5441-5450, 2002 | 161 | 2002 |
Ligation of CD28 receptor by B7 induces formation of D‐3 phosphoinositides in T lymphocytes independently of T cell receptor/CD3 activation SG Ward, J Westwick, ND Hall, DM Sansom European journal of immunology 23 (10), 2572-2577, 1993 | 159 | 1993 |
Inhibition of PI3K Signaling Spurs New Therapeutic Opportunities in Inflammatory/Autoimmune Diseases and Hematological Malignancies. FJGB Matthew D, CEW Stephen G. Pharmacological Reviews 64 (4), 1027-54, 2012 | 154 | 2012 |
Do phosphoinositide 3-kinases direct lymphocyte navigation? SG Ward Trends in immunology 25 (2), 67-74, 2004 | 148 | 2004 |